"RT Plus Chemo Triples PFS In Limited Metastatic Lung Cancer" - Roxanne Nelson, BSN, RN

Accrual was halted early after an unplanned interim analysis found a significant improvement in PFS in the SAbR plus maintenance chemotherapy arm. In addition, rates of local control and delay in distant metastases favored combination therapy. Among patients who received consolidative local therapy, there were no recurrences in original sites of gross disease; there were seven failures in the patients who received only maintenance therapy. "This study is encouraging for patients suffering from metastatic lung cancer, as metastatic lung cancer is incurable, and the standard treatment is chemotherapy alone," commented Kenneth Rosenzweig, MD, professor and system chair of radiation oncology at the Icahn School of Medicine at Mount Sinai. "This study shows that treating small tumors with highly focused stereotactic radiation can improve survival with minimal toxicity and a high level of convenience," he said. "Since this study is so small, its results will need to be confirmed in a larger study."

- Kenneth Rosenzweig, MD, Professor, System Chair, Radiation Oncology, Icahn School of Medicine at Mount Sinai

Learn More